BB Biotech provides investors with focused access to the biotechnology sector and combines this exposure to biotech innovation with active portfolio management, disciplined risk management and a transparent approach to capital allocation. As a listed investment company with permanent capital and a clearly defined dividend policy, BB Biotech represents a differentiated strategy for long-term value creation across market cycles.
Advancing human health through long-term investment in biotechnology innovation
BB Biotech invests in biotechnology companies developing and commercializing breakthrough drugs that address significant unmet medical needs.
WHAT BB BIOTECH STANDS FOR
Long-term investors in the future of medicine
For more than 30 years, BB Biotech has stood for long-term, conviction-driven investment in innovative biotechnology companies. As a listed investment company with permanent capital, we provide focused access to scientific innovation, combining deep sector expertise with a disciplined and repeatable investment approach.
Investing in breakthrough science
We focus on biotechnology innovators developing differentiated therapies for serious diseases and high unmet medical needs, with the potential to improve patient outcomes.
Conviction-driven, long-term investing
As a listed investment company with permanent capital, we invest with a long-term horizon across development cycles, independent of short-term market movements or fund flows.
A disciplined, research-led approach
Investment decisions are based on deep scientific analysis, fundamental valuation and active portfolio management, supporting consistency, risk discipline and investment performance.
Pioneer with over 30 years of experience
Depth of expertise is driven by a highly specialized investment team combining long-standing investment experience with strong medical expertise
Fundamental, return-driven investing
We invest with a clear long-term return objective, grounded in fundamental analysis, disciplined stock selection and active risk management across the full investment cycle.
OUR INVESTMENT APPROACH
How we invest in breakthrough science
01
We start with the science
We focus on differentiated therapies addressing serious diseases and high unmet medical needs, grounded in deep scientific and medical expertise and rigorous fundamental analysis.
02
We apply a disciplined investment process
Each investment must meet clearly defined return and risk criteria, supported by fundamental valuation, structured conviction assessment and risk-adjusted catalyst analysis.
03
We manage risk and realise value
We run a focused portfolio and actively allocate capital around clinical milestones, valuation inflection points and strategic outcomes, including partnerships and M&A.
Long-term performance, built stock by stock
Share price return (YTD)
+1.11%
NAV return (YTD)
+0.40%
Benchmark return (YTD)
-0.04%
As at 30 September 2025
14.60%
14.10%
9.30%
8.80%
7.10%
6.40%
14.60%14.10%9.30%8.80%7.10%6.40%01 Jan 2010 - 01 Jan 2010
An error occurred - no data to display
Share Price
NAV
Nasdaq Biotech
insights & responsibility
Investor reports and disclosures
Investor reports and disclosures
View all reportsResponsible investing
Read our sustainability strategy"We invest in companies improving patient outcomes."
Sustainability factors integrated into investment analysis.
Included in SPI ESG Index.
CONNECT WITH BB BIOTECH